1. Home
  2. PHIO vs CURX Comparison

PHIO vs CURX Comparison

Compare PHIO & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$0.65

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Logo Curanex Pharmaceuticals Inc

CURX

Curanex Pharmaceuticals Inc

N/A

Current Price

$4.70

Market Cap

9.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PHIO
CURX
Founded
2003
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
9.7M
IPO Year
2011
2024

Fundamental Metrics

Financial Performance
Metric
PHIO
CURX
Price
$0.65
$4.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 53.7K
7.5K
Earning Date
11-05-2026
09-09-2025
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.70
$0.21
52 Week High
$1.88
$13.33

Technical Indicators

Market Signals
Indicator
PHIO
CURX
Relative Strength Index (RSI) 27.10 38.26
Support Level N/A $4.34
Resistance Level $1.12 $4.71
Average True Range (ATR) 0.07 0.28
MACD -0.01 -0.18
Stochastic Oscillator 5.14 8.05

Price Performance

Historical Comparison
PHIO
CURX

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

About CURX Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.

Share on Social Networks: